Drug Trial Radar · NCT00540618
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
Last checked: Nov 20, 2026Latest source record: Nov 28, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Sep 2001
Primary completion
Not stated
Study completion Jul 2003
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.
Conditions
- Plaque Psoriasis
Interventions
MEDI-507Drug
Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
PlaceboOther
MEDI-507Drug
Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
MEDI-507Drug
Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biological activity will be assessed primarily by the Psoriasis Activity and Severity Index (PASI)Time frame: Days 14, 28, 42, 56, 70, 91, 107, and 167
Locations
43 sites in 2 countries. Site status is shown where the registry gives one.
MDS Pharma Services (US) Inc.
Phoenix, Arizona
Bressinck-Parker-Dinehart-Sangster Dermatology, PA
Little Rock, Arkansas
Associates in Research, Inc.
Fresno, California
nTouch Research Corporation
San Diego, California
Solano Clinical Research
Vallejo, California
Dermatology Specialists, Inc.
Vista, California
Colorado Medical Research Center, Inc.
Denver, Colorado
Cherry Creek Dermatology
Denver, Colorado
The Savin Center, PC
New Haven, Connecticut
North Florida Dermatology Associates, PA
Jacksonville, Florida
ICSL-Clinical Studies
Sarasota, Florida
Comprehensive Research Institute
Tampa, Florida
Atlanta Dermatology, Vein & Research Center, LLC
Alpharetta, Georgia
Northwestern University Medical School
Chicago, Illinois
Research Solutions, LLC
Evansville, Indiana
The South Bend Clinic
South Bend, Indiana
Massachusetts General Hospital
Boston, Massachusetts
FutureCare Studies
Springfield, Massachusetts
Washington University School of Medicine
St Louis, Missouri
University of Medicine & Dentistry of New Jersey Robert Wood Johnson Medical School and Clinical Research Center
New Brunswick, New Jersey
Probe Inc.
Riverside Park, New Jersey
Associates in Dermatology Research
Rutherford, New Jersey
Sadick Research Group
New York, New York
Mount Sinai School of Medicine
New York, New York
Wake Forest University School of Medicine
Winston-Salem, North Carolina
University Dermatology Consultants, Inc.
Cincinnatti, Ohio
Oregon Medical Research Center, PC
Portland, Oregon
Northeast Clinical Research Center
Allentown, Pennsylvania
Paddington Testing Company
Philadelphia, Pennsylvania
Radiant Research
Philadelphia, Pennsylvania
Clinicalm Partners-LLC
Johnston, Rhode Island
Harmony Clinical Research, Inc.
Johnson City, Tennessee
Dermatology Consultants, PC
Nashville, Tennessee
Veteran's Administration Medical Center
Nashville, Tennessee
Breco Research, Ltd.
Houston, Texas
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas
The Dermatology Centre
Calgary, Alberta, Canada
NewLab Clinical Research
St. John's, Newfoundland and Labrador, Canada
Queen Elizabeth II Health Sciences Center
Halifax, Nova Scotia, Canada
Probity Medical Research
Waterloo, Ontario, Canada
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.